{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T23:01:32Z","timestamp":1701903692529},"reference-count":33,"publisher":"FapUNIFESP (SciELO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physis"],"published-print":{"date-parts":[[2011]]},"abstract":"<jats:p>Este estudo objetivou realizar uma avalia\u00e7\u00e3o econ\u00f4mica das anticitocinas adalimumabe (ADA), etanercepte (ETA) e infliximabe (IFX) para o tratamento da artrite reumatoide no Estado do Paran\u00e1, sob a perspectiva do SUS. Os dados de efic\u00e1cia e seguran\u00e7a dos tratamentos foram buscados na literatura, e os custos foram calculados com valores gastos pelo SUS para cada um dos tratamentos. Foi elaborado o modelo de Markov para obter a rela\u00e7\u00e3o custo-efetividade de cada tratamento. A rela\u00e7\u00e3o custo-efetividade incremental (ICER) comparado ao tratamento padr\u00e3o tamb\u00e9m foi calculada para cada anticitocina. An\u00e1lises de sensibilidade e taxas de desconto foram aplicadas. Na avalia\u00e7\u00e3o custo-efetividade, encontraram-se custos por QALY de R$ 511.633,00, R$ 437.486,00 e R$ 657.593,00 para ADA, ETA e IFX, respectivamente. O ICER por QALY foi R$ 628.124,00, R$ 509.974,00 e R$ 965.927,00 para ADA, ETA e IFX, respectivamente. Nas an\u00e1lises de sensibilidade, o ETA e o ADA apresentaram valores pr\u00f3ximos. Cabe aos gestores p\u00fablicos e aos m\u00e9dicos prescritores a escolha adequada para cada paciente, entre os tratamentos disponibilizados.<\/jats:p>","DOI":"10.1590\/s0103-73312011000200002","type":"journal-article","created":{"date-parts":[[2011,8,5]],"date-time":"2011-08-05T12:36:55Z","timestamp":1312547815000},"page":"359-376","source":"Crossref","is-referenced-by-count":5,"title":["Avalia\u00e7\u00e3o econ\u00f4mica das anticitocinas adalimumabe, etanercepte e infliximabe no tratamento da artrite reumatoide no Estado do Paran\u00e1"],"prefix":"10.1590","volume":"21","author":[{"given":"Rafael","family":"Venson","sequence":"first","affiliation":[{"name":"UFPR"}]},{"given":"Astrid","family":"Wiens","sequence":"additional","affiliation":[{"name":"UFPR"}]},{"given":"Cassyano Janu\u00e1rio","family":"Correr","sequence":"additional","affiliation":[{"name":"UFPR"}]},{"given":"Michel Fleith","family":"Otuki","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Ponta Grossa"}]},{"given":"Monica Cavichiolo","family":"Grochocki","sequence":"additional","affiliation":[{"name":"Secretaria de Sa\u00fade do Estado do Paran\u00e1"}]},{"given":"Deise Regina Sprada","family":"Pontarolli","sequence":"additional","affiliation":[{"name":"Secretaria de Sa\u00fade do Estado do Paran\u00e1"}]},{"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[{"name":"UFPR"}]}],"member":"530","reference":[{"issue":"7","key":"ref1","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/ard.2004.027565","article-title":"Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden","volume":"v. 64","author":"BANSBACK N. J.","year":"2005","journal-title":"Ann Rheum Dis","ISSN":"http:\/\/id.crossref.org\/issn\/0003-4967","issn-type":"print"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/0272989X8300300403","article-title":"The Markov process in medical prognosis","volume":"v. 3","author":"BECK J. R.","year":"1983","journal-title":"Med Decis Making","ISSN":"http:\/\/id.crossref.org\/issn\/0272-989X","issn-type":"print"},{"key":"ref3","first-page":"5","article-title":"Social and economic impact of inflammatory arthritis","author":"BERGMAN M. J","year":"2006","journal-title":"Postgrad Med","ISSN":"http:\/\/id.crossref.org\/issn\/0032-5481","issn-type":"print"},{"issue":"3","key":"ref4","first-page":"151","article-title":"Update on the Brazilian Consensus for the Diagnosis and Treatment of Rheumatoid Arthritis","volume":"v. 47","author":"B\u00c9RTOLO M. B.","year":"2007","journal-title":"Rev Bras Reumatol"},{"key":"ref5","series-title":"Pharmacoeconomics in Perspective: a primer on research, techniques, and information","first-page":"116p","author":"BONK R. J.","year":"1999"},{"key":"ref6","series-title":"Portaria SCTIE n\u00ba 66 de 6 de novembro de 2006. SA\u00daDE, M. D. Aprova o Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas-Artrite Reumat\u00f3ide, na forma do Anexo desta Portaria","first-page":"31","volume":"212","year":"2006"},{"key":"ref7","series-title":"Diretrizes Metodol\u00f3gicas: Estudos de Avalia\u00e7\u00e3o Econ\u00f4mica de Tecnologias em Sa\u00fade","year":"2009","edition":"1"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/rheumatology\/keg451","article-title":"Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK","volume":"v. 43","author":"BRENNAN A.","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1590\/S0104-42302007000500026","article-title":"Artrite reumatoide e aterosclerose","volume":"v. 53","author":"BRENOL C. V.","year":"2007","journal-title":"Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira","ISSN":"http:\/\/id.crossref.org\/issn\/0104-4230","issn-type":"print"},{"key":"ref10","first-page":"1","article-title":"A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness","volume":"10","author":"CHEN Y.F.","year":"2006","journal-title":"Health Technol Assess","ISSN":"http:\/\/id.crossref.org\/issn\/1366-5278","issn-type":"print"},{"issue":"10","key":"ref11","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1002\/1529-0131(200010)43:10<2316::AID-ANR20>3.0.CO;2-6","article-title":"A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis","volume":"v. 43","author":"CHOI H. K.","year":"2000","journal-title":"Arthritis Rheum","ISSN":"http:\/\/id.crossref.org\/issn\/0004-3591","issn-type":"print"},{"issue":"64","key":"ref12","first-page":"1","article-title":"Infliximab and Etanercept in Patients with Rheumatoid Arthritis: A Systematic Review and Economic Evaluation","author":"COYLE D.","year":"2006","journal-title":"Technology Report"},{"key":"ref13","series-title":"Essentials of Economic Evaluation in Healthcare","author":"ELLIOTT R.","year":"2005"},{"issue":"6","key":"ref14","first-page":"727","article-title":"American College of Rheumatology","volume":"v. 38","author":"FELSON D. T.","year":"1995","journal-title":"Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum"},{"key":"ref15","series-title":"T\u00e1bua Completa de Mortalidade - Ambos os Sexos - 2007"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/1529-0131(199902)42:2<347::AID-ANR18>3.0.CO;2-P","article-title":"Economic consequences of the progression of rheumatoid arthritis in Sweden","volume":"v. 42","author":"KOBELT G.","year":"1999","journal-title":"Arthritis Rheum","ISSN":"http:\/\/id.crossref.org\/issn\/0004-3591","issn-type":"print"},{"issue":"9285","key":"ref17","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","article-title":"Rheumatoid arthritis","volume":"v. 358","author":"LEE D. M.","year":"2001","journal-title":"Lancet","ISSN":"http:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"issue":"6","key":"ref18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri2094","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis","volume":"7","author":"MCINNES I. B.","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"ref19","series-title":"Essentials of Pharmacoeconomics","author":"RASCATI K. L.","year":"2009"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1445-5994.2004.00710.x","article-title":"Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis","volume":"34","author":"ROBERTS L.","year":"2004","journal-title":"Intern Med J"},{"issue":"12","key":"ref21","first-page":"93","article-title":"Artrite reumatoide","volume":"57","author":"SATO E. I.","year":"2000","journal-title":"Revista Brasileira de Medicina","ISSN":"http:\/\/id.crossref.org\/issn\/0034-7264","issn-type":"print"},{"issue":"8","key":"ref22","first-page":"554","article-title":"Artrite Reumatoide","volume":"60","author":"SILVA R.G.","year":"2003","journal-title":"Revista Brasileira de Medicina","ISSN":"http:\/\/id.crossref.org\/issn\/0034-7264","issn-type":"print"},{"key":"ref23","series-title":"Reumatologia: princ\u00edpios e pr\u00e1tica","author":"SKARE T.L.","year":"1999"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.18553\/jmcp.2007.13.s1.7","article-title":"The comparative safety and effectiveness of TNF-alpha antagonists [corrected]","volume":"13","author":"SOLOMON D. H.","year":"2007","journal-title":"J Manag Care Pharm"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making: a practical guide","volume":"v. 13","author":"SONNENBERG F. A.","year":"1993","journal-title":"Med Decis Making","ISSN":"http:\/\/id.crossref.org\/issn\/0272-989X","issn-type":"print"},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2165\/00019053-200624120-00006","article-title":"Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis","volume":"24","author":"SPALDING J. R.","year":"2006","journal-title":"Pharmacoeconomics","ISSN":"http:\/\/id.crossref.org\/issn\/1170-7690","issn-type":"print"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/oxfordjournals.rheumatology.a031494","article-title":"Pharmacoeconomics of drug therapy for rheumatoid arthritis","volume":"39","author":"TUGWELL P.","year":"2000","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"ref28","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/art.23374","article-title":"Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis","volume":"58","author":"WAILOO A. J.","year":"2008","journal-title":"Arthritis Rheum","ISSN":"http:\/\/id.crossref.org\/issn\/0004-3591","issn-type":"print"},{"key":"ref29","series-title":"Pharmacoeconomics","author":"WALLEY T.","year":"2004"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-3083.2009.02296.x","article-title":"A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis","volume":"70","author":"WIENS A.","year":"2009","journal-title":"Scand J Immunol","ISSN":"http:\/\/id.crossref.org\/issn\/0300-9475","issn-type":"print"},{"issue":"12","key":"ref31","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s10067-009-1233-9","article-title":"A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis","volume":"28","author":"WIENS A.","year":"2009","journal-title":"Clin Rheumatol","ISSN":"http:\/\/id.crossref.org\/issn\/0770-3198","issn-type":"print"},{"issue":"8","key":"ref32","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00296-009-1111-4","article-title":"A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis","volume":"30","author":"WIENS A.","year":"2010","journal-title":"Rheumatol Int","ISSN":"http:\/\/id.crossref.org\/issn\/0172-8172","issn-type":"print"},{"issue":"8","key":"ref33","first-page":"1710","article-title":"Prevalence of rheumatoid arthritis","volume":"33","author":"YURDAKUL S.","year":"2006","journal-title":"J Rheumatol","ISSN":"http:\/\/id.crossref.org\/issn\/0315-162X","issn-type":"print"}],"container-title":["Physis: Revista de Sa\u00fade Coletiva"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/physis\/v21n2\/a02v21n2.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T19:38:52Z","timestamp":1638214732000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0103-73312011000200002&lng=pt&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011]]}},"alternative-id":["S0103-73312011000200002"],"URL":"https:\/\/doi.org\/10.1590\/s0103-73312011000200002","relation":{},"ISSN":["0103-7331"],"issn-type":[{"value":"0103-7331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}